First Header Logo Second Header Logo

A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumors.

Moulder SL, Mahany JJ, Lush R, Rocha-Lima C, Langevin M, Ferrante KJ, Bartkowski LM, Kajiji SM, Noe DA, Paillet S, Sullivan DM. A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumors. Clin Cancer Res. 2004 Nov 01; 10(21):7127-35.

View in: PubMed